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ABSTRACT 
 
Exosomes are biologically active extracellular vesicles, whose size range from 30 to 
100nm, which are released by many cell types in various body fluids. These particles 
have been proved to be strong players in cell-cell communication, thus reaching interest 
especially about their involvement in cancer progression, invasion and metastasis. For 
example, our group has already investigated the tumor supporting function of exosomes 
released by Glioma-Associated Stem Cells (GASC).  
Considering the mechanism of action of exosomes, besides the undeniable role exerted 
by the message they deliver, much interest is now focused on to their physical properties, 
since they could also influence the biological function observed, as shown for 
bioengineered nanoparticles, and consequently their therapeutic potential.  
As exosomal size is nanoscopic, the estimation of particle size and density has been 
elusive, and the use of several techniques has been applied, such as Transmission 
Electron Microscopy (TEM), Atomic Force Microscopy (AFM), Nanoparticle Tracking 
Analysis (NTA) and Dynamic Light Scattering (DLS), each displaying strength and 
weaknesses. Moreover, another extremely relevant matter, for which it has not yet 
reached a consensus, regards the ideal method to isolate exosomes, as it could lead to 
different exosomal populations with different features.  
In this thesis, we compared the exosomes preparations obtained by two different  
enrichment methods, wondering if this could affect the exosome uptake by cells and their 
ability to alter the biological functions of target cells. Therefore, we isolated exosomes 
released by patient-derived high-grade GASC and human glioblastoma cell line A172 in 
cell supernatants using both ultracentrifugation (UC) and ExoQuick (EQ) precipitation 
methods. Then we assessed the purified particles both for their physical properties 
(characterizing particle size and particle density) using AFM and NTA, and molecular 
properties (evaluating total protein content and a specific exosomal marker) using 
Bradford, BiCinchoninic Acid Assay (BCA) and CD9 ELISA assay. Then we performed cell 
uptake assays to observe the differential internalization of the preparations, and finally 
we evaluated whether this differential internalization could influence glioma cell 
motility.  
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Our results demonstrate that polymer-based precipitation results in particles that have 
a size distribution smaller than that of ultracentrifuge-isolated ones. Moreover, we 
further established that smaller exosomes are better uptaken by the receiving cells and, 
furthermore, this affects cell motility.  
These data suggest that the isolation method could profoundly affect the size distribution 
of the obtained exosomal preparation and this is associated with differences in their 
physical and biological properties, thus improving or decreasing their potential 
therapeutic capability.  
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1 INTRODUCTION 
1.1 GLIOMAS AND GLIOMA ASSOCIATED STEM CELLS 
Gliomas are the most common neuroepithelial tumor type and account for the 77% of all 
human brain tumors 1,2. Based on World Health Organization classification, the most 
malignant form of glioma is grade IV, which includes the glioblastoma multiforme (GBM), 
which represents the most aggressive extremity of the diffuse astrocytoma spectrum 2. 
Unfortunately, GBM is also the most common astrocytic pathology and its average 
incidence rate is 2-3 per 100.000 people 2. The median overall survival of these lethal 
tumors is around 15-18 months and less than 3% of the patients survive 5 years after 
diagnosis 2. 
Gliomas possess a very heterogeneous range of phenotypes that makes challenging their 
clinical management 1. Currently, wide genome studies have been conducted to better 
characterize gliomas3,4. Although many progresses have been made in the prognostic 
stratification of patients and in the identification of novel biomarkers, no hints about 
possible innovative therapeutic strategies have been obtaining. Thus, this fatal cancer 
still needs further exploring 3,4. For this reason, much attention has been directed not 
only to the genetic changes occurring in the tumor initiating cells, but also to glioma 
tumor microenvironment 5–7. This latter has recently arisen much attention in the 
attempt to dissect “messages” and interaction pathways with the tumor cells. In fact, it 
has already been assessed that the microenvironment plays a key role in tumor 
proliferation, invasion, aggressiveness and metastasis. It is therefore important to 
exploit the “cross-talk“ between the tumor initiating cells and the tumor 
microenvironment to identify novel target opportunities 5–7. 
This section will focus on the general overview of the pathology, reporting the 
epidemiology, etiology, histopathology diagnosis and therapy of this aggressive 
neoplasia. Moreover, there will be a section focusing on the tumor microenvironment 
and its role in cancer progression. Finally, we will introduce the Glioma Associated Stem 
Cells, GASCs. This population is constituted of activated mesenchymal stem cells 
representative of the glioma microenvironment, since able to increase the glioma 
aggressiveness through the release of extracellular vesicles, named exosomes, which we 
will be further explored in the sequent section. 
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1.1.1 GENERAL OVERVIEW OF THE PATHOLOGY 
Glioblastoma represents a neoplasia characterized by poor prognosis, with a median 
survival of only 14–16 months, despite a multimodal treatment including surgery, 
cytotoxic chemotherapy and radiation 1,3 
Since 1950s, the classification of tumors of the Central Nervous System (CNS) was based 
merely on the histologic evaluation, possible through histochemical analysis such as 
hematoxylin-eosin staining, able to suggest the tumor cell of origin, differentiation levels, 
presence of infiltration/necrosis and the vascularization of the tumor tissue 2,9. Further 
improvements were made in the classification of gliomas through the introduction of the 
immunohistochemical detection of Glial Fibrillary Acidic Protein (GFAP), antigen 
KI67/E3 ubiquitin-protein ligase MIB1 (Mib-1), tumor suppressor protein p53, and later 
on Isocitrate DeHydrogenase (IDH) 1,2. Recently, as the new diagnostic scenario has 
shifted toward biomolecular investigations to stratify gliomas, new routine analyses, 
such as Fluorescent In situ Hybridization (FISH) to verify 1p19q co-deleted genotype and 
molecular investigations on the O6-alkylguanine DNA alkyltransferase (MGMT) 
methylated status and Epidermal Growth Factor Receptor (EGFR) amplification, have 
been introduced 1,2. These new assays are not only able to better stratify glioma patients, 
but add molecular parameters to the previous WHO classification of CNS tumors and 
glioblastomas 1,2.   
According to the 2016 CNS WHO classification, glioblastomas are now divided in tree 
main variants:  
  IDH-wild type GBM  generally defined as primary GBM, is the most frequent tumor 
subtype (almost 90% of cases) and has a late onset (over 55 years) 
 IDH-mutant GBM  generally called secondary glioblastoma, is compatible with lower 
grade gliomas that underwent progression; is less frequent (10% of cases) and with an 
earlier onset with respect to IDH-wild type GBM 
 Not otherwise specified (NOS) GBM  GBM where IDH mutation couldn’t be assessed  
 
The differences between IDH wildtype and IDH mutant glioblastomas are indicated in 
Table 1.   
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Table 1 Key characteristics of IDH-wildtype and IDH-mutant glioblastomas. From Louis et al. 2016 
 IDH-WILDTYPE 
GLIOBLASTOMA 
IDH-MUTANT 
GLIOBLASTOMA 
SYNONYM PRIMARY 
GLIOBLASTOMA, 
IDH-WILDTYPE 
SECONDARY 
GLIOBLASTOMA, IDH-
MUTANT 
PROPORTION OF GBM 90% 10% 
MEDIAN AGE AT 
DIAGNOSIS 
AROUND 62 YEARS AROUND 44 YEARS 
MALE TO FEMALE RATIO 1.42:1 1.05:1 
MEDIAN LENGTH OF 
CLINICAL HYSTORY 
4 MONTHS 15 MONTHS 
MEDIAN OVERALL 
SURVIVAL 
SURGERY+RADIOTHERAP
Y 
SURGERY+RADIOTHERAP
Y+CHEMOTHERAPY 
 
 
9.9 MONTHS 
15 MONTHS 
 
 
24 MONTHS 
31 MONTHS 
TERT PROMOTER 
MUTATIONS 
72% 26% 
TP53 MUTATIONS 27% 81% 
ATRX MUTATIONS EXCEPTIONAL 71% 
EGFR AMPLIFICATION 35% EXCEPTIONAL 
PTEN MUTATIONS 24% EXCEPTIONAL 
Recently the lack of effective treatment for these pathologies has been attributed to the 
newest concept of glioblastoma as a “molecularly  heterogeneous disorder” 1,3. This 
realization induced researchers to look deeper into the molecular landscape of these 
tumors, trying to understand and profile the pathology10. The Cancer Genome Atlas 
(TCGA) attempted a classification of the molecular variants present in GBM, thus 
stratifying this tumor in four molecular subclasses. Based on the genomic, epigenomic 
and transcription profile, these four classes were referred as neural, proneural, classical 
and mesenchymal 11. Figure 1.1 displays the epigenetic classification of GBM that 
comprehends six classes, instead. 
Even though it is not yet clear whether this classification can have an impact on the 
current therapeutic strategies, the future direction is to take advantage of molecular 
analyses not only to improve the prognostic stratification of the patients but to develop 
optimal and targeted treatments in a precision medicine approach 1. 
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Figure 1.1 Graphical summary of key molecular and biologic characteristics of glioblastoma subgroups. From 
Weathers and Gilbert, 2014. 
 
GLIOBLASTOMA TREATMENT 
Glioblastomas, being the most aggressive form of glioma, despite an aggressive 
treatment still possess an extremely poor prognosis 1,12–14. Multimodal approaches are 
actually employed in the treatment of this neoplasia. Up to these days, the management 
of glioblastoma patients includes radical surgery, fractionated beam photon radiation 
and chemotherapy using temolozomide (TMZ) 15,16. Despite the best efforts, this therapy 
could improve the median overall survival of not more than 10 months, pushing 
researches into assessing new putative targets to be tested in clinical trials and in 
defining new biomarkers able to support the decision-making process. As explained 
above, genomic analyses are providing interesting insights on potential innovative 
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therapies 1,17. Moreover, antiangiogenic therapies and immunotherapy are now under 
evaluation in several clinical trials  1,3,18.  
Regarding anti-angiogenic treatments, results have not been encouraging but it is 
undeniable that the exploitation of the pathways through which angiogenesis inhibitors 
act might be fundamental for a better understanding of tumor growth and drug-
resistance processes. This knowledge could permit us to include antiangiogenic agents 
in the present therapies as a support to the current state-of –the-art treatments.  
More comforting are the results obtained through immunotherapy, and for this reason, 
more and more trials are being currently developed and devised 3,14,19–21. 
 
1.1.2 PRECISION MEDICINE AND THE IMPORTANCE OF THE TUMOR 
MICROENVIRONMENT 
In January 2015, U.S.A President Obama introduced a new initiative termed Precision 
Medicine approach 22. 
This model implies shaping therapies and treatments accordingly to specific 
biomolecular peculiarities of the patient. This approach relies on the ability to stratify 
patients in subpopulations, which differ from each other for biological or molecular 
features that can affect their response to treatments and prognosis 22. This way, specific 
therapies could be administered to specific classes of patients, sparing side effects and 
expenses to those who could not benefit from it. In this new concept the keywords are 
“stratification” and “subpopulations”, which means that precision medicine is not 
personalized (i.e. tailored to the individual patient), but aims at finding, on the basis of 
several epidemyologic, clinical and biomolecular features, homogeneous subgroups of 
patients that share common prognostic markers and/or response to therapy 22. Since 
glioblastoma, as previously explained, is a pathology that shows a heterogeneous clinical 
behavior, it is safe to say that this new initiative could fit well in the precision medicine 
scenario 22.  
In the search of prognostic markers, recent studies identified hallmarks that not only 
belonged to the actual tumor cells, but also to the tumor microenvironment (TME) 
surrounding and communicating with these cells,  which raised much attention 5,6,23. This 
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concept was first addressed in the late 1970s by Haddow and Dvorak that referred to 
tumors as “non-healing wounds”, thus reconsidering the hypothesis of tumor cells as the 
only key players in the tumor establishment 24. Later, in the 2000s, Hanahan and 
Weinberg remarked the idea of the tumor niche as a dynamic entity in which different 
cell types and molecules are involved in a harmful cross talk that results in tumor 
initiation and progression 25. The term microenvironment refers to all cells (e.g. blood 
vessels, immune cells and fibroblasts), vesicles and molecules that surround tumor cells 
and interact with them, as well as to the extracellular matrix 23,26,27. In numerous solid 
tumors, the TME cells have been reported as fundamental in tumor progression, 
resistance and metastasis, even though the origin of these tumor-supporting cells is still 
unclear (from resident cells that are activated to bone marrow cells that migrate toward 
the tumor site) as well as the mechanisms of their activation (possibly epigenetic) 5,23. It 
is increasing the knowledge that glioma stem cells (GSC) and the tumor niche are 
continuously modeling and influencing each other in a dynamic cross talk 6,28. 
Gliomagenesis and glioma progression is no exception to this topic, thus many authors 
revealed the endless and extended interaction between glioma stem cells and the glioma 
microenvironment as an important player in the development of the pathology 6,28. Up to 
now, two specialized niches have been identified in the glioma microenvironment as 
possible preservers of the GSC self-renewal ability, the vascular and the hypoxic niche 
18,31–33. In addition, vascular cells, microglia, peripheral immune cells, activated 
astrocytes and neural precursor cells are being studied as important players in the 
pathologic progression. For these reasons, the study of the glioma microenvironment 
could provide powerful insights on new molecular targets that lead to new therapies for 
the “treatment” of the microenvironment 18,31–33. 
In fact, the TME, through the release of trophic factors and enzymes, is able to influence 
GSC that, on the other hand, could signal to the TME promoting immune escape, 
resistance and invasion.  
Moreover, many stroma elements of the TME have been revealed as strong predictive 
and prognostic markers, thus leading to new potential therapeutic targets, which are 
currently being investigated 5,23,27. One of the benefits of targeting the TME instead of the 
GSCs is that TME cells are fairly genetically stable, thus easier to study and less prone to 
develop resistance to treatments.  
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To summarize, the tumor-associated stroma acts as an active player in tumorigenesis 
and contributes to tumor progression by sustaining tumor proliferation, inducing 
angiogenesis, avoiding immune destruction, deregulating cellular energetics, inducing 
invasion and metastasis 29,30. 
 
Figure 1.2 The perivascular (A), hypoxic (B) and invasive (C) GBM niche. From Hambardzumyan and Bergers, 
2015. 
 
THE THERAPEUTIC OPPORTUNITY 
As already described above, the TME constitutes a very interesting target to exploit for 
tumor therapy and treatment 5,23. In fact the TME, unlike the genetically instable GSCs, 
can be less prone to develop drug resistance. For this reason, attention has shifted to 
therapies directed to the TME and its cross talk with the tumor cells, encouraging the 
development of novel clinical trials 5,23. 
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As the contribution of the TME to cancer can be either pro-tumorigenic or, at least in the 
initial phase of tumor development, oncosuppressive, the new frontier is, instead of 
ablating the tumor-TME cross talk, to “re-educate” the TME to send specific 
antitumorigenic messages. In this way, the TME cure could become the keystone for the 
disruption of the tumor itself7.  
In this regard, the development of in vitro culture models of the glioma 
microenvironment could be an essential step to better assess the biological and 
molecular features of TME 5,23 (see next paragraph). This could be important either to 
study specific therapies aimed at blocking the activation of the TME or its communication 
with cancer cells or to search for novel diagnostic, prognostic and predictive markers. 
Next step would be the development of in vivo models of pathology strictly resembling 
the human tumor to directly assess the in vivo efficacy of putative drugs 5,23.  
GASC ARE A POPULATION OF STEM CELLS WITH TUMOR- SUPPORTING 
FUNCTION 
Our laboratory developed a novel approach to efficiently isolate and culture multipotent 
adult stem cells from different adult tissues, such as heart, bone marrow and liver 34–36. 
Applying this protocol to gliomas, we were able to obtain a population of cells that were 
not tumor initiating, but had stem properties as well as tumor supporting features 37. This 
achievement lead us to the idea that we could efficiently isolate mesenchymal stem cells 
associated with the glioma microenvironment. For this reason, we named these cells 
Glioma Associated Stem Cells, or GASC. Since 2006, more than 300 glioma samples, both 
from high-grade and low-grade gliomas, were isolated with this protocol and, despite the 
stringent culture conditions, almost 300 cell cultures were established. Moreover, we 
demonstrated that these cell lines matched the International Society for Cellular Therapy 
criteria required to be defined mesenchymal stem cells for their immunophenotype and 
functional features 37. These multipotent cells could be easily propagated in culture and 
maintain an activated phenotype. Table 2 gathers all the GASC properties and through 
which assays they were assessed.  Specifically, in vitro experiments were performed to 
assess the stem cell phenotype, clonogenicity and multipotency 37.  
Table 2. Summarized features of GASC cells. From Bourkoula et al. 2014. 
 14 
 
MORPHOLOGY Fibroblast-like morphology, confirmed by the expression of 
mesenchymal cell markers (CD90, CD73, CD105) 
UNDIFFERENTIATED 
PHENOTYPE  
Expression of pluripotent state specific transcription factors 
(OCT-4, Nanog, Sox-2) as well as of early intermediate 
filaments (Vimentin e Nestin). 
CLONOGENICITY Elevated clonal self-renewal and maintenance of an 
undifferentiated state. 
MULTIPOTENCY Ability to differentiate through the neural (neuronal, glial and 
oligodendrocytic cells), mesodermic and endodermic 
lineages.  
PRO-TUMORAL 
ABILITY 
High anchorage-independent growth ability and pro- 
aggressive behavior on tumoral cell lines through the release 
of exosomes  
 
All data confirmed that this in vitro model represented the activated glioma 
microenvironment, and led us to explore whether it could be used to predict patient 
prognosis 37. Indeed, GASC surface markers were able to prognostically stratify patients 
since they correlated with both patient overall survival and malignant progression free 
survival 37. This ultimate data supported the bounty of this in vitro patient-based model 
and the possibility to use it to customize healthcare in a precision medicine approach.   
In order to find putative targets that could be exploited for novel therapeutic strategies, 
besides describing the peculiar features of GASC, attention has been subsequently 
focused on understanding how these cells exerted their tumor supporting function,  37. 
In this regard, we showed that GASC interact with tumor cells by modulating their 
adhesive properties and releasing “messages” under the form of exosomes 37,38.  
The first property of GASC was assessed using sophisticated methods of Atomic Force 
Microscopy and elastic module algorithms. We verified that GASC cells, not only have a 
harder texture than GSC, but are also able to modify the adhesive properties of 
glioblastoma cells. This reveals that studying cell adhesion and elasticity could uncover 
interesting phenomena in the GASCs-GSCs interaction 38.   
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Another attractive field of study is the interaction between the microenvironment and 
glioma stem cells through the release of extracellular vesicles, among which exosomes 
represent an interesting topic of research 37. As described below, these particles are 30-
100 nm nanovesicles that are released from many cell types in many body fluids sending 
messages under the form of their molecular “cargo” constituted by DNA, RNAs, mRNAs, 
microRNAs and proteins 39. For this reason, these vesicles are considered important 
players in the intercellular communication 39. One of the first laboratories demonstrating 
the potential of these particles on the glioma setting was the one of Breakefield, who not 
only demonstrated that glioblastoma cells release exosomes, that contain pro-
tumorigenic messages, but also that they can affect neighbor as well as distant cells 
through the bloodstream 40. Regarding the TME, similarly to what shown in breast 
tumors, were exosomes released from tumor-associated fibroblasts have been revealed 
to induce a metastatic phenotype in breast tumor 41, GASC exosomes were able to support 
the tumor growth by increasing the biological aggressiveness of both commercial 
glioblastoma cell lines and patient-derived GSC. 
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1.2 EXOSOMES 
Research has always focused its attention on the mechanisms that undergo intercellular 
communication. In fact, much literature has been published on cell-cell contact or 
exchange of molecules, such as lipids, proteins and nucleotides 42–44.  
For this reason, since in the 1980s extracellular vesicles (EV) have been discovered as a 
powerful tool for cell-cell communication, increasing interest has been addressed in that 
direction. The key of their peculiarity is their outer composition, as it is constituted of a 
phospholipid bilayer (compatible to one of which cells are composed) 45.  
Since the beginning, EV have been sub-classified in different classes (e.g. microvescicles, 
oncosomes, exosomes, ectosomes, apoptotoic bodies) based on their biogenesis, origin, 
composition and function. Although the classification is still under implementation, there 
is a class of these vesicles, which is actually being intensively studied, whose literature, 
in the last 10 years, has been multiplied almost twenty times. These vesicles, named 
exosomes, are still under deep investigation, but the scientific community agrees in the 
importance of these particles in cell-cell communication 39,42. Although they are being 
thoroughly investigated just in these past 10 years, Johnstone et al. first reported their 
existence in 1983, as vesicles obtained from reticulocytes’ culture media 45.  
This chapter will firstly present a general identikit of these vesicles (Figure 1.3), 
describing their content and functions, especially in gliomas, which makes them so 
intriguing. Then we will proceed with the description of the current issues concerning 
the manipulation of these particles, from the isolation to the quantification, describing 
each available method and trying to speculate about the putative best isolation and 
quantification approach.  
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Figure 1.3 General features of exosomes. From Bang and Thum, 2012. 
 
1.2.1 EXOSOME GENERAL FEATURES, CONTENT AND FUNCTION  
Exosomes represent a class of cell-derived nanovesicles that originate from the 
endosomal pathway and are released through different mechanisms from cells to the 
extracellular space in several biological fluids 39,42,46–49. Their size ranges between 30 and 
150 nm diameter and from a molecular point of view they are known to express specific 
protein markers such as CD63, CD9, CD81, Alix, TSG101 and hsp70 39,42,46–49 (Table 1.4).  
The exosomal content, which only in part reflects the producing cell, includes mRNAs, 
microRNAs, DNA and proteins (Figure 1.6). This knowledge is the key to their function 
and importance, as they could be considered important players in intercellular 
communication, both locally and systemically. This should be attributed to the fact that, 
due to their biogenesis, exosomes are composed of a lipid bilayer which makes extremely 
easy for the particles to be internalized by target cells, as the composition is virtually the 
same of the cell membranes 39,42,46–49.  
Their content, as well as their surface protein expression, renders these nanoparticles 
very interesting in the diagnostic field and in the search for innovative clinical 
biomarkers 50.  
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Regarding their mechanism of action, exosomes are considered to be secreted from most 
cellular types and to be received by most cells, thus inducing genotypic and phenotypic 
changes in the recipient cell. For this reason, in the specific tumor environment 
exosomes are known to be profoundly involved in the delivery of pro-tumorigenic, pro-
invasion and pro-metastasis messages to the neighbor cells 51,52. 
 
Figure 1.4 Attributes of Exosomes. From Mathivanan and Simpson, 2010 
 
BIOGENESIS 
Conversely to shedding microvescicles, exosomes are known to derive from the 
multivesicular bodies, which are a specialized subset of endosomes 43 (Figure 1.4). These 
vesicles are integrated in the endocytic system and, once the multivesicular bodies fuse 
with the plasma membrane, exosomes are released in the extracellular space. The 
formation of these nanovesicles could occur in two different ways: the first mechanism 
depends on the Endosomal Sorting Complex Responsible for Transport (ESCRT), while 
the second one is independent from this complex 43 (Figure 1.5). It is not excluded that 
the exosomes’ production could vary depending on the cell type and the exosomal 
content. Still, the biogenesis of exosomes is a complex and elusive mechanism, which 
requires further investigations 43.  
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Figure 1.5 Molecular mechanisms of ESCRT-dependent (A) and –independent (B) exosomes’ biogenesis. From 
Abels and Breakefield, 2016. 
 
COMPOSITION 
Many approaches have been adopted in order to analyse exosomes’ protein content, such 
as: i. mass spectrometry (MS), western blotting, fluorescence-activated cell sorting 
(FACS) and immuno-electron microscopy 53. The exosomal content varies because of 
many factors, such as the cell type, differentiation stage and specific features of the cell 
of origin 48,54.  
 
Figure 1.6  RNA species found in EVs. From Abels and Breakefield, 2016. 
Even though their composition might change, some proteins were detected as constant 
in exosomes, no matter the origin 43,46,55. Some of these proteins are tetraspanins (CD63, 
CD81 and CD9), proteins involved in the membrane trafficking and fusion (Rabs family 
and several annexins), ribosomal proteins, metabolic enzymes, heat-shock proteins 
(HSP60, HSP70, HSPA5, CCT2 and HSP90), Alix, clathrin and TSG101 (Figure 1.7). 
 20 
 
Moreover, there are some other proteins that could be considered cell-specific and can 
be used to recognize cell-specific exosomes (e.g. CD61 for platelet-derived exosomes)  
43,46,55.  
 
Figure 1.7 A graphical representation of the protein composition of exosomes categorized as per function 
performed. From Mathivanan and Simpson, 2010 
 
INTERNALIZATION 
The exosome-mediated intercellular transfer of both proteins and nucleic acids has, 
nowadays, attracted considerable attention as exosomes may promote the development 
of cancer and other pathological conditions 51,56. Although the functional effects of 
exosomes mostly rely on the internalization and the subsequent release of contents in 
recipient cells, the elucidation of their uptake mechanisms and how these may be 
targeted remains an important challenge 57. The understanding of these mechanisms can 
be used to use/develop exosomes as therapeutic agents. In fact, unlike nanoparticles 
synthesized in vitro, exosomes that are released from host cells are not cytotoxic and can 
transfer information to specific cells, based on their composition and the substance in/on 
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the exosome 58. The putative mechanisms of internalization of EVs are summarized in 
Figure 1.8. 
Figure 1.8 Proposed molecular machineries involved in EV (exosome/sMVs) secretion and recipient cell 
uptake. From Xu et al. 2016 
 
Therefore, drug delivery by exosomes could be a novel mean to transport small molecule 
drugs to specifically target tissues or cells in a non-cytotoxic manner. Recent evidences 
indicate that an exosomal drug delivery system is feasible, safe, and may be efficacious 
against multiple diseases in the future56-58. Nanoparticles escape the vasculature through 
leaky endothelial tissue by the Enhanced Permeability and Retention effect (EPR effect), 
a process known as “passive targeting” 47. This is a size-specific property of nanoparticles 
circulating in the blood stream. Particles must possess a specific size in order not to be 
entrapped in the interstitium, thus flow through blood45. Depending on the experimental 
system used, particles of ~20–100 nm in diameter are very efficiently delivered to target 
tissues. As comparing sizes of exosomes released from different types of cells, it is 
considered that certain types of cells may release extracellular vescicles of a smaller than 
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20–30-nm size range, altering the size of exosomes may be a way to affect tissue 
targeting and enhance biological responses 58. 
FUNCTION 
As the knowledge on these particles increased, the more attraction exosomes gained. 
Numerous functions have been hypothesised for the role of these particles in many 
biological processes 39,46,47,52. In immunology, for instance, exosomes carry antigens that 
are processed by antigen presenting cells and presented to T cells, thus influencing 
adaptive immunity, but can also carry molecules that promote innate immune responses 
61. Moreover, evidences, from our laboratory among many others, report that exosomes 
are able to affect tumoral progression37.  
One of the main features of exosomes that makes them so interesting is their function as 
shuttles in cell-cell communication 62,63. These nanovesicles, in fact, are very efficient in 
delivering messages from the producing to the recipient cell under the form of DNA, 
RNAs and proteins. This exchange of genetic material is fundamental as it could induce 
modification in the expression pattern, protein content and function of the recipient cell, 
thus influencing its physiopathology 39,64 (Figure 1.9).  
This concept is the most attractive feature of exosomes, as they could be used as 
biologically active vectors that could send specific signals from one cell to another tumor 
cells’. Exosomes, for example could contain specific RNA that activate, in target cells, 
pathways that promote tumour progression 39,64 (Figure 1.9).  
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Figure 1.9 EV-mediated effects promoting tumor growth, invasiveness, and metastasis. From Tkach and Thery, 
2016. 
 
This concept opens a new interesting field for diagnostic studies based on the analysis of 
exosomes, in particular their content, as a way to detect the “signature” of a physiological 
or pathological state 65. As they are easily accessible (they can be obtained from many 
biological fluids such as saliva, urine, blood, ascites, etc.), the analysis of the exosomes 
contained in the biological fluids could be used as new diagnostic and prognostic 
markers and can allow obtaining information on the diseased tissue without requiring a 
biopsy 65.  
Moreover, the use of exosomes could also be therapeutic in many different conditions, 
such as cancer or immune diseases. Regarding cancer, although in many articles 
exosomes are identified as tumor promoters 51,67, it is still not excluded that exosomes 
could have some kind of anti-tumoral properties 68. Nonetheless, the prevalent idea is to 
“engineered” exosomes with oncosuppressive signals to be used in the patient 56,66. This 
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new approach is named “EXOcure” 66. So far, many trials have started, especially in 
degenerative syndromes and cancer, although much is still left to further investigation66-
68.  
 
EXOSOMES AND GLIOMAS 
As previously mentioned, in 2008 Skog et al. reported that glioblastomas secrete a 
population of nanovesicles that promote tumor progression through the delivery of 
genetic material, such as RNA, and proteins, and that these vesicles could be used as tools 
for diagnostics 40. 
Al-Nedawi et al. as well as Li et al. reported the undeniable activity of exosomes as 
carriers of the oncogenic protein EGFRvIII and coding/non-coding RNAs, respectively, in 
gliomas 69,70. 
Still, the mechanisms underlying the influence of exosomes in GBM progression and its 
communication with the tumor microenvironment is still to be understood. 
Furthermore, glioma-derived exosomes have been considered as key players in the 
tumor microenvironment activation and in the mechanisms of increased proliferation, 
angiogenesis, invasion, clonogenicity, and immune-resistance 74,75. 
Nowadays, researchers are spending huge efforts on different sides, trying to exploit the 
potential of exosomes either as putative biomarkers, as immune-tolerant vectors and 
targets to interfere with for the tumour-microenvironment communication,  47,64.   
 
1.2.2 THE ELUSIVE NATURE OF EXOSOMES: ISSUES ON EXTRACTION AND 
QUANTIFICATION METHODS 
Considering the enormous clinical potential of these particles, it is fundamental to 
develop methods that allow obtaining highly purified preparations of homogenous and 
functionally competent nanoparticles, devoid of contaminants and precisely quantified 
50,77. This would be important also for biodistribution studies or just for mere molecular 
characterization of these nanovesicles.  
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Literature on the methods to isolate and purify EVs is extremely vast, but still no gold 
standard has been totally approved among the scientific community and comparative 
studies are rare 50,53,54,59,76,77.  
Another important issue is the lack of methods to assess the actual purity of the EV 
preparations. The latter is pivotal especially for functional studies, such as uptake 
studies, cell-cell communication and activation 78.  
Finally, quantifying exosomes is a mandatory step necessary for therapeutic applications  
50,82. There are various methods, some optical and some non-optical, that have been 
developed to measure or quantify the particles 79–81. These measurements are usually 
strictly based on one feature of the vesicles, such as size, scattering properties or 
molecular features (total protein content or exosome-specific protein content of the EV 
preparation). Still, no method is able to exactly represent the whole EV population but 
the research is moving in that direction, confirming the bounty of the potential of 
extracellular vesicles as well as their relevance in the clinical context 79–81.  
1.2.2.1 EXOSOME ISOLATION METHODS 
The isolation of extracellular vesicles, and specifically of exosomes, could be obtained 
through different techniques (Figure 1.10). These methods include differential 
centrifugation, filtration, polymer and immuno-precipitation and microfluidics 59,76,82,83. 
The oldest procedure was ultrafiltration, followed by ultracentrifugation that has been 
improved for the study of viruses by Svedberg in the 1920s. Later, immunoaffinity 
purification has been used as a technique for their isolation. These methods, 
appropriately developed, have been applied for the isolation of extracellular vesicles and 
even if nowadays a gold standard has not been commonly approved for exosomes 
isolation, it is believed that a combination of these methods could reach the desired 
levels of concentration yield and purity 59,83. Over 60% of authors performing researches 
on extracellular vesicles are known to use a combination of methods, among which size 
exclusion chromatography, filtration and density gradient centrifugation are the most 
used 59,83.  
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Figure 1.10 Primary exosomes’ isolation methods reported in literature. From Gardiner et al., 2016. 
 
CENTRIFUGATION 
As shown in Figure 1.10, centrifugation methods have always been the most used to 
purify exosomes. In fact, this technique is applied in 80% of all exosomes purifications 
59,83.  
The protocol of isolation involves an initial centrifugation at low speed to eliminate 
bigger particles, followed by high-speed centrifugations (100,000-120,000x g) in which 
extracellular vesicles are pelleted 84.  
Much attention is needed in the setting of the parameters of the ultracentrifuge, such as 
rotor (fixed angle, swinging bucket), viscosity of the sample and speed specifics. 
Obviously, there could be a discrimination of particles based on their size, as the more 
dense/heavier particles could be precipitated easier than the lighter and less dense ones 
84. The density indeed could be due to the amount of the exosome cargo. Moreover, the 
“weight” of the particles could influence their precipitation, meaning that heavier 
particles are more likely to precipitate earlier rather than lighter particles, which might 
need longer time or higher speed, thus selecting specific subpopulations of EVs 84. A 
possible occurrence might be the aggregation of EVs with contaminants or with each 
other, and for this purpose, resuspension in phosphate buffer solution (PBS) and 
subsequent centrifugation might be needed to remove further impurities, despite the 
possibility of diminishing the yield 84.  
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An implementation of the initial protocol, in order to obtain a purer sample of EVs is to 
add a density gradient step. Density gradient centrifugation enables us to locate EVs in a 
floating sucrose gradient efficiently separating protein aggregates and contaminants 
from the EVs 84.  
Many authors describe numerous variations of the original protocol, depending on the 
assays that are needed to be performed (such as functional or molecular) and based on 
features such as yield or protein, RNA and total exosomes required and levels of purity 
from contaminants  50,53,59,76,77,85. 
SIZE EXCLUSION 
One other common method for the enrichment of samples in EVs is either using filters or 
chromatography 84.   
The fist method is achieved using specific size filters in which the particles smaller or 
larger than a certain number are excluded. The aim is to retain the desired particles in 
the filter 82–84.  
Using the same concept, column chromatography permits the enrichment of a specific 
EV population by the sequential elution in a single column. Usually, the filters used are 
0.8 m (for removal of large contaminants) and 0.2 m (for EVs concentration) 50.  
Nevertheless, as these vesicles appear to be particularly delicate, it is possible to damage 
the sample when processed through much smaller or larger pores. Despite this, the 
method enables not only the enrichment of the sample, but also the concentration of the 
sample itself. For this reason, these procedures are preferred as combined to other 
methods, such as ultracentrifugation or polymer precipitation 83,86.  
IMMUNOAFFINITY ISOLATION 
The technique of immuno-affinity isolation is based on the recognition of specific 
proteins situated on the surface of the EVs. The protein-antibody bond enables us to 
select the marker positive EVs or eventually to negatively select the other populations 86.  
In this procedure, the matrix is bonded covalently to EVs-specific antibodies that permit 
the enrichment in EVs through low-speed centrifugations or magnetic affinity 
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procedures. This method, as the size exclusion one, is usually associated with other 
techniques. One of the benefits of this method is its high specificity, which is fundamental 
either in case of purification or in case of enrichment of the sample in a specific 
population. Conversely, this approach has a relative low yield, and the stringent 
conditions applied could identify just one population that is positive to the specific 
marker, depleting the sample of the other EVs subpopulations 50,86.  
MICROFLUIDICS 
Beside polymeric compounds, also novel microfluidic devices have been developed in 
order to isolate EVs. One of these methods require a device that using the antibody-EV 
surface marker is able to isolate EV from sera as well as culture media. Most of these 
methods are actually used for non-biological nanoparticles and are currently being 
readapted to isolate biological EVs based on their biological properties, although many 
progresses still need to be done 86.  
POLYMERIC PRECIPITATION 
As enrichment of EV has become a high lucrative goal, many commercial kits have been 
released, among which the most used is Exoquick (System Bioscience), involving the use 
of polymeric compounds that embody isolation potential 86. These kits generally require 
an overnight incubation and a subsequent centrifugation. These methods have been 
largely used as they require little expertise and work time. Moreover, it has been 
reported that this technique has the highest recovery in terms of small EVs 
subpopulations as well as RNA 59,83. On the other hand, these methods result in a less pure 
sample, affecting the actual yield of the preparation in terms of quality. In fact it has been 
demonstrated the presence of non-exosomal contaminants (such as serum or medium 
proteins) that co-precipitate with the actual EVs. For this reason, it is important to assess 
the features of the enriched sample depending on the further uses this sample is needed. 
Another important consideration is the source of EVs, as there are some samples, such 
as saliva, in which authors describe Exoquick method as the best one to isolate exosomes, 
despite the impurities present in the preparation 85 
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1.2.2.2 EXOSOME QUANTIFICATION METHODS 
It is obvious that before investigating the functional or therapeutic ability of the particles, 
they should be biophysically characterized 50. Their particular small size is at the same 
time their strength (from a functional point of view) and our weakness as exosomes can 
be below the sensitivity level of many characterization and quantifying methods. 
Nowadays, novel methods for detection and quantification are being developed and 
assessed. It is important to acknowledge that, as for the isolation methods, there is not a 
certifiable gold standard for the detection and quantification of particles 83,86.   
As mentioned previously, quantitative and qualitative methods of detection of EVs could 
be distinguished in optical and non-optical and it is accepted that each method need 
further optimization and standardization 83,86. At the 2012 International Society of 
Extracellular Vesicles (ISEV) workshop in New York City, among various topics, the 
methods for detection of EVs have been thoroughly discussed, and the most used are 
represented in Figure 1.11 83,86.  
 
Figure 1.11 Methods used for EV characterization reported in literature. From Gardiner et al. 2016 
 
On this subject, Van der Pol et al. was able to provide measurements of exosomes using 
different optical and non-optical methods and compare them with that measured by 
transmission electron microscopy (TEM), which was considered as the gold standard 
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83,86. In the following discussion on this challenging issue, we will review the most 
common methods, reporting, when possible, comparative studies  79–81. 
ELECTRON MICROSCOPY TECHNIQUES 
The gold standard among the optical methods for detection of EVs is Electron Microscopy 
(EM). The protocol implies, with or without paraformaldehyde fixation, the staining of 
the particles with heavy metals (uranyl-acetate or osmium tetroxide) in order to contrast 
the vesicles 81,83,86. This method is extremely useful to characterize the size and the 
morphology of exosomes 83,86. Another technique is the immunogold-TEM, in which 
surface markers are bonded to gold nanoparticles that precipitate and therefore are 
detectable through transmission electron microscopy. Other techniques include cryo-EM 
and SEM (scanning electron microscopy) 83,86. Though extremely useful, these techniques 
have the flaw that are not quantitative and not only requires specialized materials and 
expertise, but they is also time consuming and susceptible to the already fragile 
preparation 86. 
ATOMIC FORCE MICROSCOPY 
Atomic force microscopy (AFM) has been recently considered as a very powerful 
instrument for the detection and characterization of nanovesicles and for this reason 
many publications on EVs report the use of this approach. This method does not require 
sample preparation, and offers a three-dimensional image of the preparation. Moreover, 
AFM gives information about the structure, the mechanical and biophysical properties of 
the sample and, if tip has been functionalized, gives a molecular readout of the EVs 
detected 86. Experimentally, AFM is based on a cantilever, appropriately set in terms of 
deflection and elastic module, which scans a surface, and reveals its topography. For this 
reason, AFM (compared with TEM in Figure 1.12)  is particularly indicated in the 
detection of nanoparticles, as the resolution of the instrument is infinitively high. This 
permits also an accurate representation of the EVs morphology 86. One the other side, as 
for electron microscopy, the technique requires very expensive instruments, is time-
consuming and gives a non-quantitative result 86.  
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Figure 1.12 Representation of size distribution comparison between TEM (red) and AFM (black).From Van der 
Pol et al., 2014  
 
OPTICAL SINGLE PARTICLE TRACKING  
An optical method to examine nanoparticles in a preparation is using specific programs 
that take advantage of nanoparticles features 86. With this purpose, Nanoparticle 
Tracking Analysis program (NTA) and Nanosight (the instrument) (compared with TEM 
in Figure 1.13) have been introduced not only for the detection of metal nanoparticles, 
as it were, but also for biological nanoparticles, such as exosomes 79,81.  
 
Figure 1.13 Representation of size distribution comparison between TEM (red) and NTA (black). From Van der 
Pol et al., 2014  
 
This method is constituted of a laser beam that scatters through the particle solution and 
based on their Brownian motion, through specific equations and algorithms, the 
program gives a read-out in terms of size distribution and concentration 79,81. NTA is 
reported as a very useful method to detect size, concentration and distributions of 
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particles, but the polydispersity of the sample could be an important deterrent in the 
estimation of the exact size of the particles. For that, very careful setting of the optimal 
parameters is required especially when we face heterogeneous populations of EVs. 
Obviously, these weaknesses are almost non-perceptible when we face a monodisperse 
solution such as a one-metal or two-metal particle solution, also because their scattering 
intensity is higher 79,81. Nevertheless, when we face a polydisperse, biological (thus less 
scattering) solution, the quantification could be challenging. A new frontier that is 
currently being exploited is the use of fluorescent NTA programs that are not only able 
to track the particles, but to recognize the fluorescently labeled ones (for example by 
antibodies recognizing specific surface markers) as the actual population we want to 
characterize 79,81. In fact, NTA is not able to establish if the particles that are detected are 
effectively the population we want to assess. For this reason, NTA is extremely useful 
once the method of isolation (especially for samples with huge amounts of contaminants, 
such as blood or saliva) is standardized and is optimized for the selective isolation of a 
specific EVs subpopulation 86.   
RESISTIVE PULSE SENSING 
Another novel instrument, commercialized for the detection of the size distribution and 
concentration of EVs, is named IZON qNano, which uses the resistive pulse sensing 
principle 86. This approach is based on the detection of single EVs that are transported 
through nanopores in a membrane (or different membranes, based on the heterogeneity 
of the preparation) by an ionic current. As the biological particles’ suspensions are 
polydisperse, this method, as well as NTA, requires different corrections and care in the 
setting of the correct protocols for detection of the whole EVs population 79,81.  
DYNAMIC LIGHT SCATTERING 
With a functioning principle similar to NTA, dynamic light scattering (DLS), compared 
with TEM in Figure 1.14, is able to detect the size distribution of an EVs preparation 86. 
Its major weak point is the fact that this method is particularly sensitive to 
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polydispersity, thus this method, although it could be improved with advanced software, 
is not particularly recommended for EVs analysis 81. 
    
Figura 1.14 Representation of size distribution comparison between TEM (red) and DLS (black). From Van der 
Pol et al., 2014 
FLOW CYTOMETRY 
Another method to characterize and detect nanovesicles is flow cytometry (compared 
with TEM in Figure 1.15) 50,86. The conventional ones are able to detect only large 
particles, such as cells and big EVs and the newer the instrument, the more sensitive it is 
to smaller particles 83,87. Some of these flow cytometer include Gallios (Beckman Coulter), 
BD-Influx (Becton Dickinson) and Apogee (Apogee Flow Systems). The protocol implies 
the use of polystyrene beads with different refractive indexes, which attach to the 
nanoparticles, making them detectable using light scatter-based flow cytometry 86. As 
controls, latex beads could be used in order to set the detection threshold and the right 
dilution. Many articles have been reported on the use of flow cytometry to detect EVs 86. 
The biggest concern with the use of this method is the actual non-detection of the 
particles per se, but the detection of the beads attached to it 86. 
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Figura 1.15 Representation of size distribution comparison between TEM (red) and scattering flow cytometry 
(black). From Van der Pol et al., 2014 
On the other hand, the method avoids the detection of protein aggregates or cell 
membrane debris. Needless to say, the technique is very sensitive and could be a useful 
tool for EVs detection; still the method needs very careful attention in setting the 
protocols 87.  
WESTERN BLOT 
Western blot assay is commonly used to detect EV-common proteins or to identify 
specific EVs subgroups 50. This technique is actually the gold standard to molecularly 
detect EVs. As previously described, the usual markers detected are tetraspanins (CD9, 
CD63, CD81, CD82), MHC molecules, or milk-fat globule-EGF-Factor VIII (MFGE8, or 
lactadherin), and cytosolic proteins such as certain stress proteins, Tsg101, Alix, or 
cytoskeletal proteins (e.g. actin, tubulin) 46. After EVs purification (either methods are 
compatible), the protocol is consistent with the one of a conventional western blot. The 
endpoint is the visualizing of the proteins by SDS-PAGE. Even if this technique is quite 
sensitive and is able to identify different populations of EVs based on their positivity to 
specific surface markers, the greatest weakness is the inability of this technique to 
discriminate the origin of the proteins detected (proteins are also present in cells or 
other EV, for examples), thus it is very sensitive to the isolation method and the purity of 
the preparations 86. Still, the minimal criteria for isolation, detection and quantification 
of EVs, are yet to be standardize. 
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2 AIM OF THE STUDY 
EVs, and especially exosomes, have been widely recognized as particles able to 
functionally modified receiving cells upon their uptake. For this reason, in the 
understanding of the communication between the tumor microenvironment and the 
tumor cells, exosomes peaked up as putative key players in this dangerous cross talk.  
For example, our laboratory has been able to isolate mesenchymal stem cells from the 
tumor microenvironment of human glioblastomas and we demonstrated that these 
Glioma Associated Stem Cells (GASC), were able to increase the biological aggressiveness 
of glioblastoma cells through the release of exosomes.  
Recently, many scientists are focusing on the possibility to take advantage of this 
naturally occurring exosomes-based cell-cell communication system to optimize novel 
therapeutic delivery systems. This approach, named “Exocure”, requires the preparation 
of highly purified and homogeneous exosomes preparations, functionally competent and 
correctly quantified. 
However, nanoparticles per se and especially the biological ones have always been 
extremely challenging in terms of purification, quantification and assessment.  
For this reason, the aim of this thesis was to characterize the exosomal population 
purified both from a commercial glioblastoma cell line (A172) and from a primary 
glioblastoma GASC cell line, comparing two different methods of isolation, 
ultracentrifugation (UC) and ExoQuick precipitation (EQ). Once we proceeded with the 
purification of the exosomes, we thoroughly characterized the populations obtained in 
terms of size distribution and frequency, by using Atomic Force Microscopy (AFM) and 
Nanoparticle Tracking Analysis (NTA), and protein content, by using BCA/Bradford 
assay and CD9 protein ELISA test. Once characterized the exosomes preparations, we 
compared their function evaluating, by both confocal microscopy and flow cytometry, 
their uptake kinetic by A172 glioblastoma cell line. Finally, A172 cells conditioned by the 
different exosomal preparations were evaluated in terms of motility changes.  
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3 MATERIALS AND METHODS 
3.1 CELL CULTURE 
3.1.1 Primary and commercial cell lines 
A172 human glioblastoma cell line was grown in Dulbecco’s Modified Eagle’s Medium 
(Sigma-Aldrich, St. Louis, MO, USA), supplemented with 10% fetal bovine serum (FBS) 
and 1% Penicillin-Streptomycin (Euroclone). Cells were maintained in monolayer 
culture at 37°C under a humidified atmosphere containing 5% CO2. 
Human glioma samples were collected by the Neurosurgery Department of the Azienda 
Sanitaria Universitaria Integrata of Udine, after a written informed consent was 
obtained, in accordance with the Declaration of Helsinki, and with approval by the 
Independent Ethics Committee of the University-Hospital of Udine. Cells representative 
of the glioblastoma microenvironment, namely the glioma associated stem cells (GASC), 
were isolated and cultured as in  37. Briefly, glioma samples were first disaggregated 
mechanically with scalpels and then enzymatically dissociated in a 0.025% Collagenase 
type II solution (Worthington) in Joklik modified Eagle’s Medium (Sigma-Aldrich) for 5 
minutes at 37°C. Collagenase activity was blocked adding a 0.1% BSA (Sigma-Aldrich) 
solution in Joklik modified Eagle’s Medium (Sigma-Aldrich). Cell suspensions were 
centrifuged at 500g for 10 minutes and filtered through a sieve (BD Falcon) in order to 
select a population less than 40μm in diameter. 
2.0 x 106 freshly isolated human cells were plated onto 100 mm human fibronectin 
(Sigma-Aldrich) coated dishes (BD Falcon) in an expansion medium (MASC) composed 
as follows: 60% low glucose DMEM (Invitrogen), 40% MCDB-201, 1mg/mL linoleic acid-
BSA, 10-9 M dexamethasone, 10-4 M ascorbic acid-2 phosphate, 1X insulin-transferrin-
sodium selenite (all from Sigma-Aldrich), 2% fetal bovine serum (StemCell 
Technologies), 10ng/ml human or murine PDGF-BB, 10ng/ml human or murine EGF 
(both from Peprotech EC). Medium was replaced with fresh one every 4 days. Once cells 
reached 70-80% of confluence, they were detached with TrypLE Express (Invitrogen) 
and re-plated at a density of 1-2 x103/cm2. 
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3.2 EXOSOME ISOLATION 
For exosomes purification, cells were cultured either in MASC medium or DMEM 
supplemented with FBS deprived of bovine extracellular vesicles by ultracentrifugation 
(100.000g for 4 hours at 4°C). Briefly, when A172 and GASC cells reached 50‐60% cell 
confluence, media were replaced with fresh ones and, after 4 days, culture supernatants 
were collected, aliquoted and kept at -20°C. Once needed, aliquots were thawed and split 
in two for differential processing (i.e. ultracentrifugation and Exoquick precipitation).  
3.2.1 Ultracentrifugation  
Ultracentrifugation of culture supernatants was performed as described in  84. Briefly, 
culture media from A172 and GASC were centrifuged at 3,000g for 30 min and the 
supernatants filtered by 0.22m syringe filters (Millipore, USA) to exclude cell debris and 
remove microvesicles. The resultant supernatants were diluted in PBS and transferred 
to 26,7ml polycarbonate tubes for ultracentrifugation at 100,000g for 90 min at 4 °C 
using a Type 70 Ti rotor in a L-80 XP ultracentrifuge (Beckman Coulter, USA). After 
removing supernatants, the pellets were washed with PBS and re-ultracentrifuged at 
100,000g for 60 min at 4 °C. The pellets were finally resuspended in 500μl PBS.  
3.2.2 ExoQuick precipitation 
ExoQuick‐TC was used to process culture supernatants for exosomes purification, 
according to the manufacturer’s protocol (EQ, System Biosciences Inc.; Mountain View, 
CA). Briefly, culture supernatants were centrifuged (3,000g for 20 minutes at 4°C) in 
order to eliminate cells and cell debris. Recovered supernatants were then mixed with 
ExoQuick‐TC solution in a 5:1 ratio and incubated for at least 12 hour at 4°C. Mixtures 
were finally centrifuged (1,500g for 30 minutes at 4°C) to obtain the exosome pellets, 
which were resuspended in 500μl PBS. 
3.3 EXOSOME SIZE ANALYSIS 
3.3.1 Atomic force microscopy 
Exosomal-preparations, obtained by both ultracentrifugation and ExoQuick, were 
diluted 1:5 in PBS to prepare a final solution of 30µl of exosomes. Samples were then 
placed on freshly cleaved 11x11mm mica sheets for 10 min and dried under a stream of 
nitrogen. AFM imaging was performed at room temperature on a BioScope Catalyst 
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controlled by a NanoScope V controller (Bruker), combined with an Eclipse TE2000-S 
inverted optical microscope (Nikon). Images were acquired in Tapping Mode using 
ScanAsyst Air probes (SCANASYST-AIR k=0.4N/m) (Bruker). 
Using Nanoscope 9.0 software (Bruker), topographic height and phase images were 
recorded at 256x256 pixels with a scan rate of 1,00Hz, a scan size of about 5μm, and a Z 
range of 3μm. Images were processed and analyzed using Gwyddion 2.37 software 
(Department of Nanometrology, Czech Metrology Institute). 
3.3.2 Nanoparticle Tracking Analysis 
Size distribution and particles concentration within samples were analyzed by 
measuring the rate of Brownian motion, using a NanoSight LM10 system (NanoSight Ltd., 
Malvern, UK) equipped with a 532nm laser and a particle tracking software.  For each 
sample, appropriately diluted in PBS (100-200 times), a video was captured for 60s each 
with a detection threshold set at 16 (maximum). Temperature was monitored 
throughout the measurements. Vesicle size distribution together with concentration 
esteem of the NTA profiles were obtained from the raw data files given by the program 
itself.  
3.4 EXOSOME QUANTIFICATION 
For the detection of the exosomal protein CD9, Europium Time- Resolved 
Immunofluorescence assay for detection of exosome antigens CD9 (TRIFIcTM Exosome 
Assay, Cell Guidance Systems) was used. Exosomal pellets were processed according to 
the manufacturer’s instructions. Protein amounts were estimated by reading the optical 
density on an Infinite 200 PRO Microplate Reader (TECAN Group Ltd., Switzerland) at 
615nm and comparing it with the standard curve supplied by the kit. Samples were run 
3 times in triplicates.  
Total exosome protein contents were quantified by using Bradford and BiCinchoninic 
Acid Assay (BCA) protein assays.  
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3.5 EXOSOME UPTAKE 
3.5.1 Confocal and epifluorescence imaging 
20.000 A172 cells were incubated for 1, 3, 6, 24, 48 and 72 hours in 10% ultracentrifuged 
FBS - Dulbecco’s modified Eagle’s medium (uDMEM) added or not with 1*109 exosomes 
labeled by DiD (Molecular Probes Invitrogen, Carlsbad, CA, http://www.lifetechnologies. 
com), according to manufacturer's instructions. Briefly, exosome preparations were 
incubated for 20 min in 1:200 DiD-labeling solution, and then preparations were re-
precipitated to eliminate the excess of fluorophore.  
To localize exosomes within a cell, nuclei were stained by adding 2mg/ml Hoechst 33342 
(Sigma) to cell cultures 15 min before imaging. At each defined time-point, DiD-labelled 
exosomes were removed and wells carefully washed before imaging. Fluorescence 
images were collected either by Leica TCS SP8 confocal microscope equipped with a 63x 
oil-immersion objective (Leica Microsystems, Wetzlar, Germany, http:// leica.com) or by 
a Leica DMI600B microscope equipped with a 40x dry objective (N.A. 0.6) and processed 
by a deconvolution software.  
3.5.2 Flow cytometry  
A172 cell cultures conditioned or not by DiD-labelles exosomes as previously described 
(3.5.1) were detached from the culture substrates by TrypLE Express solution (Gibco — 
Life Technologies). Detached cells were washed and resuspended in 200μl of calcium-
and magnesium-free Phosphate Buffered Saline (PBS) before performing cytometric 
analyses.  
Flow cytometry was performed on a FACSverse flow cytometer (BD Biosciences) on cells 
detached from substrates with TrypLE Express solution (Life Technologies), washed and 
resuspended in 200 µl PBS. After reaching a count of 1x104 cells, the data were gated on 
the basis of forward and side scattering and the mean fluorescence intensity (MFI) was 
calculated as the ratio between total DiD fluorescence over the number of cells showing 
fluorescence for both DiD and Hoechst. For each time point, experiments were 
performed in triplicate and at least 10.000 cells per replica were analyzed. All the 
analyses were performed by using FlowJo V.10 software. 
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3.6 FUNCTIONAL ASSAY 
In order to evaluate the in vitro cell motility of A172 conditioned or not by exosomes 
precipitated, either by Exoquick or ultracentrifugation, from both A172 and GASC 
supernatants, a scratch assay was performed. 2*104 cells were seeded onto a 24-well 
(33mm2 area) plate and when reached high cellular confluence, a scratch was created 
using a 200µl tip. Phase contrast images of the scratches were acquired every 6 hours, 
until their complete closing, utilizing either Nikon Eclipse TS100 (Nikon) or Leica 
DMI6000B. Briefly, the motility (µm/hour) was estimated by measuring, by ImageJ 
software, the average width of the scratches at different time points.  
3.7 STATISTICS  
Statistics was performed by either Minitab 17 or Graphpad Prism 5.0 (La Jolla, CA, USA). 
AFM and NTA size data were fitted with a lognormal probability density function to 
determine the peak size. Results are presented as mean ± standard deviation (SD). Paired 
or unpaired t-test, as appropriate, was used to compare continuous variables between 
two groups. For uptake and scratch assays, repeated measurements one-way ANOVA 
followed by Bonferroni post-test was used. In the case of the motility assays using 
decreasing concentrations of exosomes, one-way Anova was followed by a test for linear 
trend. For size, uptake and migration measurements, unless indicated, a p value less than 
0.05 was considered significant. 
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4 RESULTS 
4.1 DIFFERENT PURIFICATION TECHNIQUES AFFECT THE SIZE 
DISTRIBUTION OF THE EXOSOMIAL PREPARATIONS 
 
Three GASC as well as A172 culture supernatants were split and exosomes were 
precipitated by two different enrichment methods, specifically ExoQuick (EQ) and 
ultracentrifuge (UC). Once the exosomal preparations were resuspended, they were 
adsorbed on mica coverslips and subsequently assessed by AFM to determine the size 
distribution of the isolated exosomes. Figure 4.1a and 4.1b for GASC and Figure 4.2a and 
4.2b for A172 are representative images obtained from EQ- and UC- preparations, 
respectively. Firstly, data collected assessed the spherical-like morphology of the 
isolated particles. Secondly, they highlighted that particles isolated through EQ had a 
smaller size with respect to those obtained by UC (Figure 4.1, Figure 4.2)  
 
This was further confirmed by interleveled size distributions, determined from the 
maximum height of the particles obtained analyzing at least 10 AFM images for each 
GASC- (Figure 4.1c) and A172- (Figure 4.2c) sample. In fact, independently form the 
source, glioma associated stem cells or commercial glioma cell line, exosomes size 
distribution vary depending on the isolation method, being exosomes enriched by EQ 
smaller than those obtained by UC. It is important to specify that these are the results 
obtained using AFM images evaluations.   
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Figure 4.1 Representative image of GASC nanoparticles obtained using EQ (a) and UC (b) precipitation methods. 
Panel c represents the size frequency distribution of both the preparations, revealing the difference in size of 
the particles isolated by EQ (n=2140) and UC (n=433), respectively. 5x5m images. Scale bar: 1µm 
 
 
Figure 4.2 Representative image of A172 nanoparticles obtained using EQ (a) and UC (b) precipitation 
methods. Panel c represents the size frequency distribution of both the preparations, revealing the difference 
in size of the particles isolated by EQ (n=840) and UC (n=426), respectively. 5x5m images. Scale bar: 1µm 
Three different preparations for each sample and for each method were then statistically 
evaluated, assessing 10 images for each sample obtained. As reported in Table 4.1, UC 
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preparations showed larger particles, with an average peak size of 81.1nm and 94.4nm 
for GASC and A172, respectively. On the other hand, AFM measurements on EQ 
preparation reported a peak size of 43.3nm for GASC and of 50.8nm for A172. For both 
A172 and GASC, the differences between EQ- and UC- precipitated exosomes were 
statistically significant, confirming the divergence of the extracellular vesicles’ size based 
on the isolation approach.  
 
Table 4.1 AFM measurements of GASC and A172 size distributions when isolated by different isolation 
methods (EQ and UC, respectively). For each exosome source, p values are indicated in the last column. 
SIZE (nm) EQ  UC  p 
GASC 43.3 ± 11.7 81.1 ± 3.9 0.0061 
A172 50.8 ± 5.7 94.4 ± 13.9 0.0074 
 
The exosomes preparations were furthermore assessed for size distribution using the 
NTA technology. It was extremely interesting to notice that NTA could not discriminate 
the difference in the size distribution between the isolation methods  
In fact, Figure 4.3a and b represent the interleveled size distributions of the particles 
isolated from GASC and A172 respectively, using EQ and UC, respectively. The graphs 
show that for GASC preparations, EQ samples had a peak size of 83.6nm, while those 
isolate in UC reported a 90.1nm peak size. Moreover, A172 isolated in EQ and UC showed 
peak sizes at 107.4 and 106.1nm, respectively.  
The inability to detect differences between EQ- and UC- preparations, could be probably 
due to the presence, in EQ preparations, of small particles whose scattering properties 
could not be detected by the camera of the NTA instrument. Indeed, previous articles 
reported that NTA is poorly able to detect particles that are below 50nm in diameter 
(that are instead clearly visible using AFM), thus deeply affecting NTA measurements 
79,81.  
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Figure 4.3 Size distribution of GASC (a) and A172 (b) exosome preparations, obtained by both EQ and UC, 
measured by NTA. For GASC preparations 567 particles for EQ and 654 particles for UC were anaòyzed; on the 
other hand, for A172 samples, 1838 EQ particles and 1820 UC particles were assessed. 
Table 4.2 reports the results obtained when all three sample in triplicate were estimated, 
confirming the lack of significant difference between samples precipitated by EQ and UC.  
 
Table 4.2 Peak size of GASC- and A172- exosomes, isolated by different isolation methods (EQ and UC, 
respectively), as assessed by NTA. p values are indicated in the last column for each exosome source. 
SIZE (nm) EQ  UC  p 
GASC 78.0 ± 7.1 80.9 ± 10.9 n.s. 
A172 92.8 ± 13.8 90.1 ± 10.0 n.s. 
 
Altogether, data obtained suggested that, for UC precipitations both quantification 
methods seemed interchangeable; nevertheless, in case of EQ preparations, AFM was 
able to detect a population of particles that was under the range of detection of NTA, 
supporting the notion that this latter method could underestimate both the actual 
concentration and the truthful size range of EQ- exosomes. This statement is consistent 
for both GASC as well as A172 samples. In fact, figure 4.4 compares for EQ- and UC- 
preparations of A172 and GASC-derived exosomes, the peak size as measured by both 
AFM and NTA. These graphs show clearly that for UC preparations AFM and NTA 
measurements are similar (Figure 4.4b), while for EQ preparations (Figure 4.4a), the size 
shifts based on the quantification method.  
 
b 
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Figure 4.4 Comparison between the size peak averages obtained from A172 and GASC samples isolated by EQ 
(a) and UC (b) using AFM and NTA. Data are presented as mean  standard deviation. p values are indicated as 
*** if p<0.0001.  
 
As literature reported DLS as another viable method to quantify nanoparticles 81, we 
assessed our sample using this approach. The first assays failed, as the instrument is 
extremely sensitive to the polydispersity of the particle. Figure 4.5 shows an attempt to 
measure GASC EQ and UC exosomes using DLS and we observed peaks consistent with 
data obtained by AFM for both samples (EQ and UC showed 41.5 ± 3.2nm and 90.1 ± 
0.7nm peaks, respectively). Despite these encouraging results, confirming data obtained 
by AFM, we also observed peaks at 500nm, probably due to aggregates or debris that 
compromised the actual measurement because of the intensity contribution of these 
particles and the evaluation of the polydispersity index of the preparation. In fact, with a 
polydispersity index of nearly 0.7, the samples often appear not suitable for DLS 
measurements.  
 
 b 
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Figure 4.5 DLS plots from GASC-extracted exosomes by EQ (a) and UC (b). The three colors represent the 
triplicate measurements. In both cases we observe two peaks, the low-scattering exosomes component and the 
high-scattering debris and aggregates (around 500 nm), respectively.  
 
 
Another discrepancy revealed using the two different methods of quantification regards 
concentration. In fact, EQ and UC did not share the same proportion between the amount 
of particles assessed by NTA and the particle density obtained by AFM (Table 4.3).  
In fact, calculating by AFM the particle density (particles/µm2) for both the UC- and EQ- 
preparations depicted in Figure 4.1c and 4.2c, and comparing the results obtained 
counting, as particles/ml, the same preparation using NTA (Figure 4.3a and 4.3b), we 
observed that EQ samples were characterized, with respect to the UC ones, by a much 
higher ratio (Table 4.3). As literature reports an NTA threshold limit of detection of 50nm 
for biological particles due to their scattering properties, we considered applying this 
cut-off to our AFM data 81. It is interesting to see that, applying to AFM data a threshold 
of 50nm, the proportion between the particles measured by AFM and NTA became 
comparable, both for A172 and GASC (Table 4.3). Thus, the NTA approach for 
nanoparticle quantification can underestimate the number of particles per volume, if 
their size is below the detection threshold, and overestimate their average size as well. 
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In our study, this was especially true when applied to EQ preparations and was 
consistent for GASC as well as for A172 preparations.  
This result is the actual proof that the below-50nm particles were the ones responsible 
for the discrepancy between AFM and NTA measurements.  
 
Table 4.3 Particle concentration as assessed by AFM and NTA measurements. Particle concentrations are 
expressed as particles/µm2 for AFM and particles/ml for NTA. The ratio between the two methods reflects the 
underestimation of NTA for particles that are below 50nm. Further calculations on AFM data, applying a 50nm 
cut-off reports a corrected particle density and thus a corrected AFM/NTA ratio, that, this time, is comparable 
between the two methods. This result is especially appreciated in the case of EQ preparations and for the A172 
sample.   
 Density AFM 
(particles/µm2) 
Concentration 
NTA 
(particles/ml) 
Ratio 
AFM/NTA 
density (a.u.) 
Density AFM 
(>50nm) 
(particles/µm2) 
Corrected 
Ratio  
AFM /NTA 
density (a.u.) 
(>50nm) 
GASC EQ 9.23 3.34E+10 2.76E-10 6.86 2.05E-10 
GASC UC 2.64 1.68E+10 1.57E-10 2.58 1.54E-10 
A172 EQ 5.82 7.80E+10 7.46E-11 3.62 4.64E-11 
A172 UC 1.66 3.37E+10 4.93E-11 1.61 4.78E-11 
 
 
4.2 THE CONTRIBUTION OF THE PURIFICATION TO UC AND EQ 
PREPARATIONS  
  
The first and most important datum obtained by exosome size analyses was that EQ 
precipitation gave a size distribution of particles that is smaller than the UC one; 
moreover, these differences are visible using AFM but are not detected by the NTA 
technology. Therefore, we tried to assess possible players responsible for the difference 
in size distribution.  
Since EQ-precipitation is based on polymers known to precipitate, together with 
nanoparticles, also proteins, to exclude the possibility that small-size nanoparticles were 
indeed an artifact due to the precipitation method, we precipitated culture media and 
buffer, both by EQ and UC,. Briefly, NTA measurements of the particle concentration in 
PBS and culture media precipitated by both methods was 4 orders of magnitude smaller 
than that measured in actual samples (thus almost negligible). Moreover, the size of the 
particles assessed by either NTA or AFM (>150nm diameter) was compatible with that 
of big precipitates and not of exosomes (data not shown).  
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In order to establish if the cut off in size that discriminates UC and EQ could be imputed 
to the ultracentrifuge inability to precipitate the smallest particles, we decided to re-
precipitate an EQ preparation using UC (Figure 4.6). Assessing the particles using AFM 
we noticed that the EQ preparation that underwent UC precipitation shifted its size peak 
from 45.3nm to 85.0 nm, compatible with the previous UC observations (Table 4.3). 
Moreover, not only the size peak was affected by the re-precipitation, but also the 
particle density measured, which shifted from 3.8 particles/µm2 (EQ) to 1.1 
particles/µm2 (UC re-precipitation). Therefore, the UC method seemed to be unable to 
precipitate small particles and therefore the resulting distribution might not be 
completely representative of the actual exosomal population. This hypothesis was 
further supported by the comparison between A172 supernatants precipitated by EQ 
and the preparations obtained by purifying these latter by UC: the smaller particles 
visible by AFM in the initial EQ preparation disappeared after precipitation by UC, 
confirming that this latter selects only the larger particles, likely mostly in the NTA range 
of detection.  
All the data considered suggest that the EQ isolation method is able to precipitate a 
population of the extracellular vescicles that is enriched in small particles and that this 
population is lost during ultracentrifugation. Therefore, ultracentrifugation might be 
responsible for a selection of the exosomal population based on size. Moreover, 
regarding quantification methods, NTA is a technique whose efficiency appears to be 
isolation method-specific. In fact, despite NTA might be suitable for UC-isolated particles, 
it might not be the most efficient quantification method when dealing with EQ-extracted 
exosomes.   
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Figure 4.5 AFM representative pictures of A172 exosomes isolated by EQ (a) and subsequently precipitation by 
UC (b). As observed by AFM measurement (c), EQ isolated exosomes increased in size (result not visible using 
NTA), probably due to the loss of small particles during the re-precipitation. Data are presented as 
meanstandard deviation.  
 
Table 4.4 AFM and NTA measurements of EQ isolated A172 exosomes and the same preparation re-precipitated 
using UC. The size difference between the two precipitations is detected by AFM, but not by NTA. Moreover, the 
particle density, as well as the particle concentration, changed considerably, demonstrating that UC is able to 
isolate the bigger particles, failing to precipitate the smallest ones that are included in the EQ precipitation.     
 
 
 
4.3 MOLECULAR ASSAYS ON EQ AND UC EXOSOMES  
 
SAMPLE AFM NTA 
 SIZE (nm) 
DENSITY 
(particles/µm2) 
SIZE (nm) 
CONCENTRATION 
(particles/ml) 
A172 EQ 
45,31 ± 
16,62 
3,8 79,67 ± 27,00 4,88*10E11 
A172 EQ_UC 
85,04 ± 
26,04 
1,05 76,03 ± 39,05 6,46*10E10 
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Methods based on protein determination in the UC and EQ preparations are not reliable 
for estimating the amount of exosomes in a sample. The data obtained by AFM and NTA 
quantification methods seem to suggest that EQ isolation method has a higher particle 
yield compared to UC.  We attempted to investigate eventual protein contaminations in 
EQ as well as UC and eventually evaluate them. We performed Bradford as well and BCA 
colorimetric assays followed by SDS-PAGE (Figure 4.7). In fact, Bradford, BCA and SDS-
PAGE show that EQ precipitation introduces an overwhelming background of proteins, 
likely due to precipitation of serum proteins from the media. The results obtained are 
summarized in Table 4.5.  
 
Table 4.5 EQ preparations have a much larger protein content than UC. Protein concentration were measured 
in triplicate using both Bradford and BCA colorimetric assays on the four samples indicated and the resulting 
concentration in µg/ml was divided by the particle density measured by NTA (particles/ml) to obtain the 
amount of protein/billion exosomes. p values are expressed as the significant difference between the isolation 
methods. 
  
Protein/billion exosomes (µg) 
Bradford assay 
Protein/billion exosomes (µg) 
BCA assay 
GASC 
EQ 5.55 ± 0.21 
p<0.0001 
6.16 ± 0.55 
p<0.0001 
UC 0.68 ± 0.08 1.43 ± 0.09 
A172 
EQ 27.53 ± 3.23 
p=0.0001 
38.02 ± 1.42 
p<0.0001 
UC 1.04 ± 0.18 1.68 ± 0.08 
 
 
 
Figure 4.6 SDS-PAGE gel reveals the protein content of 0.5x109 exosomes preparations from GASC isolated using 
EQ (1) and UC (2). Lanes 3 and 4 are the same setting using A172 supernatant (EQ and UC, respectively). Lane 
5 shows the Bio-Rad Dual Colour Standard protein marker, whereas lane 6 was loaded with Bovine Serum 
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Albumin (molecular weight = 66 kDa) and 7 with FBS. The resulting gel reveals a greater protein content in EQ 
preparations rather than UC preparations. 
 
All of these methods have revealed to be unfit to efficiently quantify the exosomal 
fraction in both preparations. Therefore, we decided to evaluate the CD9 content of the 
preparations through a CD9 ELISA assay that combined with NTA, estimates the 
exosomal content of each sample. CD9 (or CD81 and CD63) detection could be used as a 
general method for exosome quantification, however exosomes from different sources 
are likely to present different amounts of these markers. In the case of uptake studies in 
which exosomes from different sources are compared, this would make the 
normalization impractical. This makes NTA still the favorite option for exosomes 
quantification, despite the limitations described above. In this case, NTA is considered 
appropriated to normalize the fluorescence intensity and the subsequent uptake 
experiments as the data, even though not perfect, give a sufficiently accurate readout. 
Moreover, from the data obtained on NTA density, it is clear that this technique was able 
to detect EQ higher particle concentration, that is consistent with the data obtained in 
AFM. Still, when discussing results, we still took into consideration the possibility that 
NTA underestimates EQ preparations, due to the instrument limits, but the discrepancy 
is mitigated by the CD9 data obtained. The results are resumed in Table 4.6.  
 
Table 4.6 EQ preparations show less fluorescence intensity associated to the exosomal marker CD9. Data are 
from an ELISA assay on equal number of particles based on the NTA measurements from table 2. Values are 
expressed in arbitrary units (a.u.) as the average fluorescence intensity ± standard deviation as well as p values 
on data acquired in triplicate. 
  Fluorescence intensity/ billion particles (a.u.) 
GASC 
EQ 207 ± 74 
p=0.0099 
UC 473 ± 67 
A172 
EQ 471 ± 136 
n.s. 
UC 542 ± 104 
 
Interestingly, EQ samples show less fluorescence CD9-associated, and especially in GASC 
preparations. This result is contrary to the previous results that state the higher amount 
of particles isolated with EQ method, thus suggesting that probably this latter, compared 
to UC, precipitates particles that are not all CD9 positive.  
The CD9 ELISA assay somehow demonstrates that the huge amount of small particles in 
EQ preparations, not detected in NTA, do not correlate with a broad increase of CD9-
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positive particles. Conversely, it seems that, when normalized to NTA particle count, CD9 
is more expressed in UC-isolated samples. This data is more relevant for GASC 
supernatants. 
Together the results imply that the NTA quantification method is fairly reliable among 
the used methods in estimating the exosomal content of a preparation.  
This statement is peculiarly true in case of A172, as the CD9/number of particles ratio is 
comparable for UC and EQ samples, hinting that the small EQ particles that are not 
detected in NTA, do not alter the CD9 content of the preparations. Regarding GASC 
culture media EQ purified exosomes show less CD9 positive particles, suggesting a lower 
exosomal content.  
Anyway we can safely say that even though NTA possibly underestimates the amount of 
particles (especially for EQ samples), it does not underestimate the number of exosomal 
amount.  
4.4 A172 CELLS PREFERENTIALLY UPTAKE PARTICLES 
PURIFIED BY EXOQUICK PRECIPITATION 
 
Once we assessed the effects of EQ and UC isolation methods on size distribution and 
particle concentration, we decided to evaluate how the different particle size affected the 
cellular uptake. To perform the internalization assays, we labelled the particles with a 
lipophilic dye, namely DiD, and conditioned approximately 20,000 A172 cells with 
0.5x109 NTA-counted labelled exosomes. Images were taken on live cells at 1, 3, and 6 
hours, confirming the actual internalization for both preparations, but in different 
amounts. In fact, as shown in Figure 4.8 and 4.9, we discovered that either GASC- 
or A172- EQ isolated particles extensively entered A172 cells within 3 hours, while 
UC preparations needed 6 hours for a significant uptake. 
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Figure 4.7 Internalization assay preformed on A172 cells (blue: Hoechst nuclear staining) by EQ- (upper 
images) and UC- (bottom images) DiD labelled (red fluorescence) GASC exosomes. The images represent the 
overlaid channels of the two emissions. Scale bar is 10 µm. 
 
 
Figure 4.8 Internalization assay preformed on A172 cells (blue: Hoechst nuclear staining) by EQ- (upper 
images) and UC- (bottom images) DiD labelled (red fluorescence) A172 exosomes. The images represent the 
overlaid channels of the two emissions. Scale bar is 10 µm. 
 
Moreover, GASC exosomes appear to be internalized more efficiently than A172 
exosomes.  
To further support the higher uptake of EQ isolated particles, FACS analyses were 
preformed to assess the mean fluorescence intensity (MFI) of DiD labelling on A172 
cells. The results, shown in Figure 4.10 and 4.11, confirmed the data obtained by 
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confocal imaging, corroborating the concept that A172 cells preferentially uptake 
EQ-precipitated exosomes (from either GASC or A172 supernatants) rather than UC-
precipitated exosomes.    
 
Figure 4.9 Flow cytometry analyses of the uptake of GASC exosomes by A172 cells. On the left, a representative 
plot showing the Hoechst-positive population (gated) assessed for DiD presence. On the right, histograms 
showing DiD expression of A172 cells conditioned, for different times, by EQ isolated exosomes (upper three 
panels at 1, 3 and 6 hours) and UC precipitated exosomes (lower three panel at 1, 3 and 6 hours). The histograms 
overlay non-conditioned A172 cells (red) and GASC exosomes-conditioned A172 cells (green). In each plot it is 
indicated the percentage of the DiD-Hoechst double positive cells and the relative mean fluorescence intensity 
ratio (MFI).  
 
 
Figure 4.10 Flow cytometry analyses of the uptake of A172 exosomes by A172 cells. On the left, a representative 
plot showing the Hoechst-positive population (gated) assessed for DiD presence. On the right, histograms 
showing DiD expression of A172 cells conditioned, for different times, by EQ isolated exosomes (upper three 
panels at 1, 3 and 6 hours) and UC precipitated exosomes (lower three panel at 1, 3 and 6 hours). The histograms 
overlay non-conditioned A172 cells (red) and A172 exosomes-conditioned A172 cells (green). In each plot it is 
indicated the percentage of the DiD-Hoechst double positive cells and the relative mean fluorescence intensity 
ratio (MFI). 
 
 55 
 
Moreover, to further assess if the uptake could reach, for EQ and UC preparations, a 
saturation point over longer times, A172 cells were incubated with DiD-labelled GASC 
exosomes for intervals of time that ranged from 1 to 72 hours. The results are reported 
in Figure 4.12a and 4.12b. The analysis showed that even if at 72 hours the fraction of 
DiD-positive cells were comparable for both EQ and UC exosomes, the first ones were 
already highly internalized at 6, 24 and 48 hours. This data could imply a different 
mechanism of uptake for the different isolated exosomes.  
 
 
Figure 4.11 Kinetic of exosome uptake. Although EQ and UC exosomes seemed to reach a saturation at 72 hours, 
the uptake kinetic was different in the two preparations. (a) Internalization assay preformed on A172 cells 
(blue: Hoechst nuclear staining) with EQ- (upper images) and UC- (bottom images) GASC exosomes labeled by 
DiD (red fluorescence). Scale bar is 50µm. (b) Quantitative analysis of the DiD positive A172 cells (%) exposed 
to EQ- (red) and UC- (blue) exosomes, respectively. Data are displayed as mean ± standard deviation and p<0.05 
(*) is calculated for EQ values versus UC ones. 
 
To exclude the hypothesis that EQ preparations showed a higher fluorescence intensity 
due to an increased affinity of the DiD dye to EQ rather than UC, fluorescence intensity 
was quantified for both the preparations. Interestingly, we found that DiD fluorescence 
was less intense in EQ preparations, as reported in Table 4.7. These data proved that the 
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increased fluorescence intensities observed in A172 cells exposed to EQ-extracted 
exosomes were most likely due to increased uptake levels, rather than to increased 
intensities of the particles. To summarize, EQ isolated particles are less prone to be 
labelled by DiD, therefore it is unlikely that their preferential uptake by A172 cells 
could be the result of a more intense labelling. 
 
Table 4.7 NTA-counted exosomal yield before and after DiD labelling and DiD fluorescence intensity of 1*109 
EQ and UC exosomes isolated both from GASC and A712. Data suggested that EQ preparations were less prone 
to labeling compared to UC. Moreover, the labelling procedure, no matter the source or the isolation method, 
determined a 90% loss of particles (comparing the first and the second column). Moreover, A172 exosomes 
seemed to be less DiD labelled, hinting a different vesicles’ composition. 
  
NTA density 
before 
labelling 
(particles/ml) 
NTA density 
after labelling 
(particles/ml) 
Fluorescence 
intensity/billio
n particles 
(a.u.) 
GASC 
EQ 3.1x1010 3.9x109 1.19x10-6 
UC 1.9x1010 2.6x109 4.05x10-6 
A172 
EQ 5.2x1010 9.7x109 1.43x10-7 
UC 2.6x1010 4.5x109 1.90x10-7 
 
As previously discussed, despite the inability of NTA to detect the total exosomal fraction, 
we could safely assume that, considering the ELISA assay, the amount of exosomes in the 
EQ preparations does not considerably varies from the putative one billion exosomes 
used for the uptake assays. On the other hand, the measurements seems acceptably 
accurate for UC samples. 
To further assess whether the enhanced uptake of EQ preparations was size-dependent, 
we re-precipitated EQ-isolated A172 exosomes by UC, followed by DiD labelling. As 
previously assessed, the size distribution shifted from 50nm to nearly 100nm, 
compatibly with the data obtained in Table 4.4. Compared to the EQ precipitated 
control, the uptake of UC re-precipitated EQ exosomes was sensibly diminished, as 
shown in Figure 4.13. These evidences hint the possibility that ultracentrifugation 
somewhat operated a selection of the bigger particles and that deeply affected the 
cellular uptake of exosomes.  
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Figure 4.12 Uptake assay on A172 cells (blue: Hoechst nuclear staining) of EQ (upper three images) and EQ 
exosomes that underwent a consequential UC (bottom three images). Exosomes were labelled using DiD (red 
fluorescence). As shown, the internalization largely decreased upon re-precipitation of EQ exosomes using UC. 
Scale bar is 10 µm. 
 
To rule out the possibility that ExoQuick itself could interfere with the internalization 
outcome observed, UC extracted exosomes were further precipitated by EQ and 
labeled by DiD. The images obtained in the uptake assay demonstrated that EQ 
precipitation did not increase the uptake of UC extracted exosomes, being this latter 
comparable to the UC precipitated control.  
 
     EQ 
1h 3h 6h 
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Figure 4.13 Uptake assay on A172 cells (blue Hoechst nuclear stained) of UC (upper three images) and UC 
exosomes that underwent a consequential EQ precipitation (bottom three images). Exosomes were labelled 
using DiD (red fluorescence). As shown, the internalization was not improved upon re-precipitation of UC 
exosomes using EQ. Scale bar is 10 µm. 
 
Furthermore, to exclude that the increased uptake of EQ exosomes coud be due to the 
serum proteins co-precipitated with exosomes by EQ (Table 4.5 and Figure 4.7), we 
decided to assess the internalization of UC precipitated exosomes resuspended in EQ-
precipitated PBS buffer and culture media. Results suggested, as displayed in Figure 4.15, 
that the protein component in the EQ precipitation did not increase the internalization 
of UC precipitated particles.  
 
 
Figure 4.14 EQ medium protein precipitation did not affect the A172 exosomes’ uptake by A172 cells. DiD is 
comparable in case of UC precipitated exosomes (a), and UC exosomes resuspended in EQ precipitated culture 
medium (b) or PBS buffer(c). Scale bar is 10 µm. 
     UC 
1h 3h 6h 
c 
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All the results obtained supported the hypothesis that A172 cells preferentially 
internalize EQ extracted exosomes and that this could be attributed to the small size of 
the EQ extracted particles. Thus, the uptake kinetics of exosomes is indirectly affected by 
the isolation method, as different purifications lead to preparations characterized by 
different particle size distributions.    
 
 
4.5 THE EFFECTS OF EXOSOMES’ DIFFERENTIAL UPTAKE ON 
FUNCTIONAL ASSAYS  
 
We previously showed that A172 cell cultures increase their motility rate when 
conditioned with GASC exosomes 37. Therefore, we decided to assess if EQ- and UC- 
extracted exosomes could induce different functional behaviors in A172 cell cultures.  
We exposed to 0.5x109 NTA-counted EQ and UC GASC exosomes the same number of 
cells and we performed a scratch assay. In this assay, we scratched a confluent cell 
culture, making an incision and measuring the velocity at which the edges of the gap 
come together through time (µm/h). Figure 4.16 shows, through the images taken at 0, 
6, 12, and 24 hours, that A172 cells incubated with EQ-purified exosomes have a higher 
motility (as they fill the incision quicker) with those conditioned with UC extracted 
exosomes compared to those not exposed to exosomes (control).  
 60 
 
 
Figure 4.15 A172 conditioned by EQ extracted GASC exosomes displayed an improved motility compared to 
those conditioned by UC exosomes. Panel a shows representative images of the assay performed. Top four 
images show the motility of A172 cells exposed to EQ exosomes at different times. Middle four images show A172 
cells exposed to UC exosomes. The bottom four images represent A172 cells that were not incubated with 
exosomes (Negative Control). Speed was calculated within the 12 hours and panel b shows the results as mean 
and standard deviation obtained from four replicates.*, p<0.05 vs. the negative control (NC). 
 
To further verify if the functional effects detected could be associated with the 
concentration of exosomes used for the conditioning, we performed further experiments 
with A172 cells exposed to different amounts of exosomes, from 10 times the one 
described in Figure 4.16, to amounts 10,000 times diluted. Figure 4.17 supported the 
existence of a possible dose-dependent effect of UC and EQ-extracted exosomes. 
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Figure 4.16 Motility assay results of the exosome concentration dilution, from 10 times higher to 10.000 times 
lower. Speed is calculated within the 24 hours, as for the previous experiment. The bar charts represents the 
mean and standard deviation obtained from three replicates. p values are calculated for the linear trend of 
dilutions.  
 
These results imply that not only the EQ preparations showed an increased uptake 
kinetic, but also that this phenomenon is correlated to an improved functionality of the 
conditioned cell culture. Moreover, the increase of speed and the effectiveness of the 
delivering of the “message” is likely dose-dependent.  
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5 DISCUSSION 
 
This thesis highlights the relevance of dissecting the morphological and physical features 
of exosomal samples instead of lingering on mere molecular characterizations. This topic 
earned much interest as exosomes are known as key players in the intercellular 
communication and they could be used in therapy as efficient nanocarriers 64.  
Considering drug delivery systems, many different types of synthetic nanoparticles have 
been realized for this purpose, such as carbon, polymeric or metal nanoparticles, that 
upon different nanobioengineering have been functionalized to be internalized by target 
cells and deliver specific molecular signals 58. Moreover, Shang et al. demonstrated that 
the uptake process was strongly influenced by the nanoparticle diameter, and defined, 
for many different cell cultures, the optimal diameter as the one ranging from 40nm to 
50nm 58. Although this aspect could have important clinical consequences, it has never 
been investigated, at least to our knowledge, for EVs.  
For this reason, we characterized exosomes isolated using two different isolation 
methods, firstly focusing on the exosomal size, as EV diameter could deeply affect the 
way nanovesicles are internalized thus altering the functional asset of the recipient cells 
88. It is important to point out that this work did not study the mechanisms of exosome 
uptake by cells, though this could be an interesting future perspective.  
In order to assess the size distribution of the UC and EQ-extracted GASC and A172 
exosomes, we decided to use an optical (NTA) and a non-optical method (AFM). Our 
findings suggested that NTA, despite its wide use to estimate the particle concentration 
of exosomal preparations, lacks in establishing the accurate size distribution of the 
sample as it fails in detecting smaller particles. This was particularly evident in the EQ 
preparations, highly enriched in small particles, as assessed by AFM. In literature, it has 
been widely recognized that the NTA detection technique gives poor results in 
estimating the number of biological and lipid particles with a diameter inferior to 50nm, 
probably because of their low scattering intensities 81. DLS was also employed as an 
optical method to quantify exosomal preparations but, as for the NTA, it requires 
extremely selected preparations, in terms of both purity and polydispersity, as non-
exosomal debris or protein aggregates could affect the scattering measurements. Despite 
these quantification method resulted in inaccurate results, a deeper morphological 
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estimation was possible using AFM. This technique, even if extremely time-consuming 
and expensive, was able to detect the size of the particles, based on the height profile that 
corresponds to the diameter of the particle attached to the mica surface. It is possible, 
though, that there could occur some isovolumetric deformation, as the particle adheres 
to the mica and thus not appearing perfectly spherical. This phenomenon has already 
been reported in various articles 38,81,89–91, but it depends on the preparation and analysis 
setting applied. However, especially for UC preparations, AFM measurements seemed to 
be comparable to the ones obtained using other detection approaches, convincing us that 
the setting we used to analyze the particles lead to a minimal deformation and an optimal 
accuracy, thus assuming a spherical shape. Furthermore, it is important to point out that 
AFM is very different from NTA and DLS. These latter, in fact, are very sensitive to 
parameters such as temperature or viscosity of the fluid, and they are taken into 
consideration to estimate the hydrodynamic diameter, the key computed algorithm 
given as read-out. AFM, on the other hand, is less perturbed by the environmental 
conditions, as the measurements are carried out in a “dry state”.  
Regarding exosomes shape, AFM analyses revealed a heterogeneous scenario. Although 
most measurements confirmed for exosomes a spherical-like shape, some of them 
resulted irregular. This phenomenon could be due to the fact that the tip size (4nm in 
average) lead to the inability to systematically study the exosomal shape.  
Considering the size distribution, we observed significant differences related to the 
isolation method, being EQ preparations, with respect to the UC ones, characterized by 
smaller size. This concept has been widely discussed by Gardiner et al., who reported an 
ISEV position paper treating, among other subjects, the diverse results obtained by 
adopting different isolation and quantification procedures 83. The article stated that, even 
though no gold standard in both processes is in place, it is important to carefully describe 
the procedures applied, as different isolation or quantification techniques could deeply 
affect the results obtained. Moreover, differences in the particle size can reflect the 
quantification method, such as the hydrodynamic diameter for NTA or AFM slightly 
deformed dry state diameter and the conditions in which EVs are measured. About this, 
Dominguez-Medina et al. reported an increase of the hydrodynamic diameter of about 
10nm caused by the proteins present in the serum that could form a “corona” that, 
surrounding the particles, could result in a raise in diameter 92.  
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For its detection limit (50nm), NTA is not ideal for the estimation of the particle 
concentration either. However, estimating the exosome amount by molecularly 
assessing CD9, an exosome specific marker, we established that NTA did not significantly 
underestimate the exosomal fraction in the EQ samples, being CD9 signal lower than that 
observed in the analogous NTA-counted UC particles. On the other hand, evidences 
report that different subsets of exosomes can differ in the amount of specific tetraspanins 
and we cannot exclude that this is the case of our experimental setting too87.  
Nevertheless, NTA has been found to be much more accurate in defining the exosomes 
density than methods based on the quantification of the protein content. As a matter of 
facts, we observed that chemical-precipitated preparations were contaminated by huge 
amounts of serum proteins, thus challenging the quantification of these samples. As this 
is a very crucial problem in the extracellular vesicles scenario, as polymeric 
precipitations are more and more used for exosome purification, many commercial kits 
are now available to evaluate exosome-specific protein markers, such as CD9, CD63 and 
CD81. This is a very attractive approach, as it would not only detect different 
subpopulations in the same preparation but also, as in our case, combined with an optical 
method such as NTA, would permit to avoid the overestimation of the exosomes by 
excluding non-exosomal vesicles possibly present in the preparations. However, it is 
important to highlight that the molecular approach could be applied only when 
comparing the same sources of exosomes, as assuming that every source retain the same 
amounts of each exosomal markers would be misleading.  
Our revealing results indicate that different isolation methods lead to particles that differ 
in terms of size distribution and that this distinction was possible using AFM. In detail, 
the particles isolated using EQ purification appeared smaller than the particles isolated 
from the same source but precipitated using ultracentrifugation. At first, these data were 
not paralleled by differences in morphology and CD9 content of the different exosomes 
preparations, but they were enlightening when we proceeded with the cellular uptake 
experiments. In fact, exosomes isolated from the same GASC supernatants by different 
methods, displayed different uptake kinetics, as EQ-extracted exosomes seemed to be 
internalized faster than the UC-precipitated ones. Performing various controls, such as 
double precipitations and checking the contribution of serum proteins and aggregates in 
EQ samples, we reached the conclusion that the effect revealed was associated with the 
size distribution of the particles 
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In order to assess if the size-dependent internalization phenomena was restricted to the 
exosomal source (GASC), we performed the same experiments using A172 EQ- and UC- 
precipitated exosomes. The results obtained confirmed the size dependent cell uptake of 
exosomes, supporting the notion that the event was not cell type-specific.  
Literature reported a huge amount of articles studying the impact of isolation methods 
on the extraction yield, morphological features and the biological properties of the 
exosomes 53,59,76,77,85. Zlotogorski-Hurvitz et al. studied exosomes from UC and EQ 
preparations isolated from saliva and found that UC exosomes were smaller than EQ, 
besides different morphology as well as molecular features 85. On the other hand, an 
article reported an increased size of UC exosomes when compared to density gradient 
precipitated particles 76,93. Density gradient precipitation has been described as an 
efficient and accurate method for the study of the downstream RNA cargo of the 
exosomes, although it is delineated by lower yields in terms of particles, when compared 
to UC and EQ 59. Although recent literature has described in detail the differences 
between isolation methods, no information are available on the effects on the uptake of 
exosomes by the recipient cells, with the exception of Franzen’s group that studied the 
kinetic of uptake of UC exosomes by gall bladder cancer cells 60. To our knowledge, this 
is the first study that compares the cell uptake of exosome preparations obtained by two 
different isolation method, and assesses the effects of the differential exosome uptake on 
cell motility.  
Our results suggested that the isolation method profoundly impact the size distributions 
of the exosomal preparations and that this was associated with differences in the uptake 
and functional abilities of isolated exosomes. Conversely to the nanoparticles described 
by Shang et al. in which size was the only property affecting cell uptake, it would be 
incorrect to expand this knowledge to exosomes 58. In fact, it could be possible that the 
different exosomes populations isolated by EQ and UC could differ not only in size, but 
also in other features, such as electrochemical membrane potential, surface proteins or 
molecular cargos, and that the functional effects observed could be the result of these 
differences. Still, our data imply that size deeply affects uptake kinetics and thus the 
biological functions of the receiving cells.  
Considering this work, EQ precipitation has been revealed as the best isolation method, 
when studying cell uptake kinetics. Indeed, small EQ-exosomes are internalized faster 
than large UC-exosomes, thus leading to an enhanced functional effect (cell motility) on 
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the recipient cells.  On the contrary, EQ samples are recognized as a highly impure 
preparation, due to the isolation method that tends to precipitate proteins or non-
exosomal aggregates and as their size could be comparable to the small EQ precipitated 
exosomes, an accurate characterization is rather challenging.   
Concerning uptake, an important path to investigate would be the internalization 
mechanisms and whether they are different depending on exosomes size or exosomes 
isolation methods. Many articles reported a wide range of mechanisms of entrance of 
exosomes, such as membrane fusion or clathrin-dependent/independent endocytosis 
57,78. Our laboratory is actually focusing on the mechanisms of entrance of exosomes, 
trying to assess the contribution of each singular pathway to the cumulative exosomal 
uptake.  
Besides these considerations, our experiments suggest that cells preferentially uptake 
smaller exosomes that, as they are endowed with increased internalization kinetics, are 
able to trigger and enhanced functional response. This knowledge has a strong impact 
on possible exosome-involving therapies. In fact, it could be useful to use the size 
parameter to select exosomal subpopulations for therapeutic use. It would also be 
extremely interesting to study exosomes produced by different cell types in terms of size, 
to better understand their contribution to the recipient cell in terms of functional 
abilities. Based on the results reported, it would seem that cells producing smaller 
exosomes would be the more effective cells in shaping the microenvironment, resulting 
more efficient in delivering their message, compared to large-exosomes producing cells. 
GASC exosomes indeed have already been proved as key players in the support of tumor 
progression. Still, the involvement of size as a parameter to take into consideration for 
the effects obtained has not been investigated yet. Some authors, currently studying this 
subject, observed a difference in exosomal size distribution between normal and 
pathological cells 90. There are still some main topics to further explore, such as the 
capacity of this differential uptake to trigger a significantly different response based on 
the physiological status of the producing cells. Systematic studies on different sizes 
observe in different cell types, their ability to promote different cellular responses would 
be extremely interesting as a future perspective, and it could take hint from the 
observations retrieved.
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